Fig. 3From: Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II TrialExploratory subgroup analysis of the two regimens for pathological complete response (pCR) TE, docetaxel and epirubicin; TX, docetaxel and capecitabine; HR, hormone receptorBack to article page